{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "25015035",
  "DateCompleted": {
    "Year": "2015",
    "Month": "05",
    "Day": "12"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "04",
    "Day": "10"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1949-2553",
      "JournalIssue": {
        "Volume": "5",
        "Issue": "13",
        "PubDate": {
          "Year": "2014",
          "Month": "Jul",
          "Day": "15"
        }
      },
      "Title": "Oncotarget",
      "ISOAbbreviation": "Oncotarget"
    },
    "ArticleTitle": "Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.",
    "Pagination": {
      "StartPage": "4581",
      "EndPage": "4602",
      "MedlinePgn": "4581-602"
    },
    "Abstract": {
      "AbstractText": [
        "Oncoprotein CIP2A a Cancerous Inhibitor of PP2A forms an \"oncogenic nexus\" by virtue of its control on PP2A and MYC stabilization in cancer cells. The expression and prognostic function of CIP2A in different solid tumors including colorectal carcinoma, head and neck cancers, gastric cancers, lung carcinoma, cholangiocarcinoma, esophageal cancers, pancreatic carcinoma, brain cancers, breast carcinoma, bladder cancers, ovarian carcinoma, renal cell carcinomas, tongue cancers, cervical carcinoma, prostate cancers, and oral carcinoma as well as a number of hematological malignancies are just beginning to emerge. Herein, we reviewed the recent progress in our understanding of (1) how an \"oncogenic nexus\" of CIP2A participates in the tumorigenic transformation of cells and (2) how we can prospect/view the clinical relevance of CIP2A in the context of cancer therapy. The review will try to understand the role of CIP2A (a) as a biomarker in cancers and evaluate the prognostic value of CIP2A in different cancers (b) as a therapeutic target in cancers and (c) in drug response and developing chemo-resistance in cancers."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Molecular and Experimental Medicine, Avera Research Institute, Sioux Falls, SD; Department of Internal Medicine, SSOM, University of South Dakota, Sioux Falls, SD."
          }
        ],
        "LastName": "De",
        "ForeName": "Pradip",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Carlson",
        "ForeName": "Jennifer",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Leyland-Jones",
        "ForeName": "Brian",
        "Initials": "B"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Molecular and Experimental Medicine, Avera Research Institute, Sioux Falls, SD; Department of Internal Medicine, SSOM, University of South Dakota, Sioux Falls, SD."
          }
        ],
        "LastName": "Dey",
        "ForeName": "Nandini",
        "Initials": "N"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Oncotarget",
    "NlmUniqueID": "101532965",
    "ISSNLinking": "1949-2553"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antineoplastic Agents"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Autoantigens"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Biomarkers, Tumor"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "CIP2A protein, human"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Intracellular Signaling Peptides and Proteins"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Membrane Proteins"
    },
    {
      "RegistryNumber": "EC 3.1.3.16",
      "NameOfSubstance": "Protein Phosphatase 2"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "pharmacology"
      ],
      "DescriptorName": "Antineoplastic Agents"
    },
    {
      "QualifierName": [
        "drug effects",
        "genetics"
      ],
      "DescriptorName": "Apoptosis"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Autoantigens"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Biomarkers, Tumor"
    },
    {
      "QualifierName": [
        "drug effects"
      ],
      "DescriptorName": "Gene Expression Regulation, Neoplastic"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Intracellular Signaling Peptides and Proteins"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Membrane Proteins"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Models, Genetic"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism",
        "pathology"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Protein Binding"
    },
    {
      "QualifierName": [
        "antagonists & inhibitors",
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Protein Phosphatase 2"
    }
  ],
  "CoiStatement": "The author(s) confirm that this article content has no conflicts of interest."
}